In vitro modulation of Bcl-2 levels in small cell lung cancer cells: Effects on cell viability

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 10, 2010, Pages 1001-1009

  Santos, A O ^a,b   Pereira, J P ^a,b   Pedroso de Lima, M C ^b,c   Simoes S ^a,b   Moreira, J N ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Antisense ODN; Bcl 2; Chemosensitization; Flow cytometry; Gene silencing; siRNA; Small cell lung cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; MESSENGER RNA; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN H2171; CELL STRAIN H69; CELL STRAIN SW2; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG SMALL CELL CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 78149263712     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500099     Document Type: Article

References (40)

1. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEER cancer statistics review (1975-2005). http://seer.cancer.gov/csr/1975_2005/.
2. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8.
3. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145: 1036-1040.
4. Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. On-cogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988; 336: 259-261.
5. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Kors-meyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
6. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110-1117.
7. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucle-otide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-876.
8. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 1027-1036.
9. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucle-otides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-1042.
10. Santos A, Sarmento-Ribeiro AB, de Lima MC, Simoes S, Moreira JN. Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer. Cytometry A 2008; 73A: 1165-1172.
11. Pfaff MW. A new mathematical model for relative quanti-fcation in real-tiem RT-PCR. Nucleic Acids Res 2001; 29: 2002-2007.
12. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
13. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, et al. Randomized phase III trial of fudarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120.
14. Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, et al. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004; 10: 3195-3206.
15. Anderson EM, Miller P, Ilsley D, Marshall W, Khvorova A, Stein CA, et al. Gene profling study of G3139- and Bcl-2-targeting siRNAs identifes a unique G3139 molecular signature. Cancer Gene Ther 2006; 13: 406-414.
16. Lai JC, Tan W, Benimetskaya L, Miller P, Colombini M, Stein CA. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A 2006; 103: 7494-7499.
17. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroen-docrine lung tumors. Oncogene 2007; 26: 6927-6936.
18. Roelle S, Grosse R, Buech T, Chubanov V, Gudermann T. Essential role of Pyk2 and Src kinase activation in neuro-peptide-induced proliferation of small cell lung cancer cells. Oncogene 2008; 27: 1737-1748.
19. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousef S, Simon HU, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005; 117: 755-763.
20. Reed JC. A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation? Leuk Res 1996; 20: 109-111.
21. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specifc nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phospho-rylation in regulating cell survival and proliferation. J Biol Chem 2004; 279: 40209-40219.
22. Supino R, Perego P, Gatti L, Caserini C, Leonetti C, Col-antuono M, et al. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Eur J Cancer 2001; 37: 2247-2256.
23. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Bous-sard T, Tibshirani R, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplifca-tion. Oncogene 2006; 25: 130-138.
24. Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, et al. Relative Bcl-2 independence of drug-induced cytotox-icity and resistance in 518A2 melanoma cells. Clin Cancer Res 2004; 10: 8371-8379.
25. Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, et al. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res 2006; 12: 4940-4948.
26. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, et al. Expression of bcl-2 - protein in small cell lung cancer. Lung Cancer 1996; 15: 31-40.
27. Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M, Hara N. Bcl-2 expression as a predictor of chemosensi-tivities and survival in small cell lung cancer. Cancer J Sci Am 1996; 2: 212-216.
28. Maitra A, Amirkhan RH, Saboorian MH, Frawley WH, Ashfaq R. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 1999; 30: 712-717.
29. Paik KH, Park YH, Ryoo BY, Yang SH, Lee JC, Kim CH, et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J Korean Med Sci 2006; 21: 35-39.
30. Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008; 59: 95-104.
31. Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. Lung Cancer 1998; 22: 1-13.
32. Soini Y, Paakko P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998; 153: 1041-1053.
33. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Commun 1999; 262: 381-387.
34. Pal'tsev MA, Demura SA, Kogan EA, Jaques G, Zende B. Role of Bcl-2, Bax, and Bak in spontaneous apoptosis and proliferation in neuroendocrine lung tumors: immunohis-tochemical study. Bull Exp Biol Med 2000; 130: 697-700.
35. Zereu M, Vinholes JJ, Zettler CG. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer 2003; 4: 298-302.
36. Abdulkader I, Sanchez L, Cameselle-Teijeiro J, Gude F, Chavez JE, Lopez-Lopez R, et al. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep 2005; 14: 1527-1531.
37. Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 2004; 3: 327-334.
38. Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Rommele M, Leja A, et al. G3139 and other CpG-containing immu-nostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 2006; 16: 83-93.
39. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
40. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979.